Cargando…

Outcomes From Cytotoxic Chemotherapy Following Progression on Immunotherapy in Metastatic Melanoma: An Institutional Case-Series

INTRODUCTION: The role of chemotherapy in the management of advanced melanoma is limited due to low response rates and short survival. Improved outcomes to chemotherapy administered after immunotherapy for metastatic melanoma and other solid tumors have been reported. We studied the outcomes of subj...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gaughan, Elizabeth M., Horton, Bethany J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9096114/ https://www.ncbi.nlm.nih.gov/pubmed/35574303 http://dx.doi.org/10.3389/fonc.2022.855782

Ejemplares similares

Immunotherapy Potentiates the Effect of Chemotherapy in Metastatic Melanoma—A Retrospective Study
por: Hadash-Bengad, Reut, et al.
Publicado: (2020)

The Promise of Liquid Biopsy to Predict Response to Immunotherapy in Metastatic Melanoma
por: Fattore, Luigi, et al.
Publicado: (2021)

Case Report: Dynamic overlap of melanoma, sarcoidosis, and targeted therapy for BRAF-mutant melanoma
por: Dar, Nakul, et al.
Publicado: (2023)

Complete Response of Metastatic Melanoma to Local Radiation and Immunotherapy: 6.5 Year Follow-Up
por: Gutkin, Paulina M, et al.
Publicado: (2018)

Pilot Study of CT-Based Radiomics Model for Early Evaluation of Response to Immunotherapy in Patients With Metastatic Melanoma
por: Wang, Zhi-long, et al.
Publicado: (2020)

Editorial: The role of immunotherapy in melanomas
por: Fateeva, Anna, et al.
Publicado: (2023)

Differences in and verification of genetic alterations in chemotherapy and immunotherapy for metastatic melanoma
por: Li, Yang, et al.
Publicado: (2021)

NK Cells in the Tumor Microenvironment as New Potential Players Mediating Chemotherapy Effects in Metastatic Melanoma
por: Garofalo, Cinzia, et al.
Publicado: (2021)

Toward Maximizing Immunotherapy in Metastatic Castration-Resistant Prostate Cancer – Rationale for Combinatorial Approaches Using Chemotherapy
por: Slovin, Susan R.
Publicado: (2012)

Gradient differences of immunotherapy efficacy in metastatic melanoma related to sunlight exposure pattern: A population-based study
por: Liu, Mengsong, et al.
Publicado: (2023)

Salvage Fractionated Stereotactic Radiotherapy with or without Chemotherapy and Immunotherapy for Recurrent Glioblastoma Multiforme: A Single Institution Experience
por: Hasan, Shaakir, et al.
Publicado: (2015)

Case Report: Clinical Characteristics and Outcomes of HIV Positive Patients With Metastatic Prostate Cancer Treated With Immunotherapy: A Case Series and Literature Review
por: Idossa, Dame, et al.
Publicado: (2022)

Comparison Between First Line Target Therapy and Immunotherapy in Different Prognostic Categories of BRAF Mutant Metastatic Melanoma Patients: An Italian Melanoma Intergroup Study
por: Marconcini, Riccardo, et al.
Publicado: (2022)

The Association of Radiation Dose-Fractionation and Immunotherapy Use With Overall Survival in Metastatic Melanoma Patients
por: Wang, Shang-Jui, et al.
Publicado: (2020)

Melanoma Immunotherapy: Next-Generation Biomarkers
por: Hogan, Sabrina A., et al.
Publicado: (2018)

Metastatic melanoma to the proximal ureter
por: DeSanto, Matthew, et al.
Publicado: (2023)

Is there still a role for cytotoxic chemotherapy after targeted therapy and immunotherapy in metastatic melanoma? A case report and literature review
por: Simon, Aurélien, et al.
Publicado: (2017)

Recent Advances in Immunotherapy in Metastatic NSCLC
por: Bansal, Pranshu, et al.
Publicado: (2016)

Perspectives on Immunotherapy of Metastatic Colorectal Cancer
por: Dai, Yongjiu, et al.
Publicado: (2021)

Rescuing Cancer Immunity by Plasma Exchange in Metastatic Melanoma (ReCIPE-M1): protocol for a single-institution, open-label safety trial of plasma exchange to clear sPD-L1 for immunotherapy
por: Davidson, Tara M, et al.
Publicado: (2022)

An Immunometabolic Shift Modulates Cytotoxic Lymphocyte Activation During Melanoma Progression in TRPA1 Channel Null Mice
por: Forni, Maria Fernanda, et al.
Publicado: (2021)

Larotrectinib in Mismatch-Repair-Deficient TRK Fusion-Positive Metastatic Colon Cancer After Progression on Immunotherapy
por: Kasi, Pashtoon M, et al.
Publicado: (2022)

Immunotherapy combined with rh-endostatin improved clinical outcomes over immunotherapy plus chemotherapy for second-line treatment of advanced NSCLC
por: Huang, Hongxiang, et al.
Publicado: (2023)

Metformin is associated with improved clinical outcomes in patients with melanoma: a retrospective, multi-institutional study
por: Augustin, Ryan C., et al.
Publicado: (2023)

Beyond PD-1: The Next Frontier for Immunotherapy in Melanoma
por: Rohatgi, Anjali, et al.
Publicado: (2021)

Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma
por: Ho, Joel, et al.
Publicado: (2022)

Human Tumor Targeted Cytotoxic Mast Cells for Cancer Immunotherapy
por: Fereydouni, Mohammad, et al.
Publicado: (2022)

Impact of cytotoxic T lymphocytes immunotherapy on prognosis of colorectal cancer patients
por: Zhu, Yankun, et al.
Publicado: (2023)

Treatment Outcome of Different Chemotherapy in Patients With Relapsed or Metastatic Malignant Urachal Tumor
por: Chen, Meiting, et al.
Publicado: (2021)

Genetic alterations in peritoneal metastatic tumors predicted the outcomes for hyperthermic intraperitoneal chemotherapy
por: Nguyen, Quynh-Anh, et al.
Publicado: (2023)

High-Metastatic Melanoma Cells Promote the Metastatic Capability of Low-Metastatic Melanoma Cells via Exosomal Transfer of miR-411-5p
por: Chen, Hao, et al.
Publicado: (2022)

Case Report: Stereotactic body radiation treatment for immunotherapy escaped oligometastatic progression in cutaneous melanoma and merkel cell carcinoma
por: Khaddour, Karam, et al.
Publicado: (2023)

PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution
por: Pernas, Sonia, et al.
Publicado: (2019)

Association of Tumor Lysis Syndrome and Metastatic Melanoma
por: Kelkar, Neil, et al.
Publicado: (2021)

Commentary: High-metastatic melanoma cells promote the metastatic capability of low-metastatic melanoma cells via exosomal transfer of miR-411-5p
por: Li, Tianhang, et al.
Publicado: (2022)

Commentary: Treatment Outcome of Different Chemotherapy in Patients With Relapsed or Metastatic Malignant Urachal Tumor
por: Szarvas, Tibor, et al.
Publicado: (2022)

Mechanisms of Immunotherapy Resistance in Cutaneous Melanoma: Recognizing a Shapeshifter
por: Thornton, Jessica, et al.
Publicado: (2022)

Editorial: The Evolving Role of Immunotherapy in Non-Melanoma Skin Cancers
por: Guida, Michele, et al.
Publicado: (2022)

Editorial: Mechanisms of resistance to the targeted therapy and immunotherapy in cutaneous melanoma
por: Premi, Sanjay, et al.
Publicado: (2022)

Research landscape and trends of melanoma immunotherapy: A bibliometric analysis
por: Liu, Yanhao, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_89c0f101j7r4strhdb1nee3cse